Global Peptide Cancer Vaccine Market & Clinical Pipeline Insight
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
With the ever increasing new cancer cases across the globe and the conventional treatment methods unable to cope up with the challenges posed by the tumor and their immune response evading techniques, cancer immunotherapy brings a ray of hope. Cancer immunotherapy allows the host’s immune cells to get sensitized with the tumor-associated antigens which in turn elicits B cell and T cell mediated immune response to target and eliminate tumor cells. This is the underlying principle of cancer immunotherapy.
Among different forms of cancer immunotherapy which includes monoclonal antibody based immunotherapy, antibody-drug conjugates, dendritic cell cancer vaccines and others, peptide cancer vaccine holds a special position due to its various inherent advantages associated with its mechanism of action, its manufacturing process and its user friendly compliance. This could be supported with the fact that the first cancer vaccine successfully launched in the market was provenge, a prostate cancer vaccine.
The market trends of peptide cancer vaccines are on a higher curve, thanks to so many favorable parameters associated with peptides. Peptide cancer vaccines are based on active immunotherapy which makes them more potent as the antibodies present in the body after the administration of the vaccine are already sensitized and are ready for their anti-tumor action. The response is permanent which lasts almost throughout the lifetime of the patient.Moreover, peptides are highly specific in their function which allows for the formulation of personalized cancer vaccine. As the tumor-associated antigens are protein sequence, they can be investigated and incorporated for the development of cancer vaccine based on that specific protein sequence to target only the tumor cells, avoiding the healthy cells hence reduced risk of toxicity.
With the development of next generation peptide cancer vaccines namely multivalent long peptides, peptide cocktail vaccines, hybrid peptide vaccines, personalized peptide vaccines and peptide-pulsed dendritic cell cancer vaccines among others, several challenges associated with the cancer immunotherapy will be addressed. The major hurdles for peptide cancer vaccines is the lack of standardized clinical trials success related parameters which has resulted in many clinical trials failures in the recent times. In addition to this, cancer cells are known to evade immune response by modulating the immune system, inducing immune-tolerance and initiating cancer-immunoediting.
What so ever be the challenges, the future of peptide cancer vaccine is extremely bright as it offers novel solutions to so many unanswered questions in cancer immunotherapy. As the knowledge of antigen, its action on the key components of the immune system is further understood, the efficacy of peptide vaccine will definitely increase. Until then, the best way forward for peptide cancer vaccine is to use multivalent long peptide sequence which is able to break immunotolerance and offer wide therapeutic action. Meanwhile investigators need to bring forward new clinical trials study parameters in line with the cancer vaccine program. For the patients at their advanced stage of cancer, the combinational therapy using conventional methods like chemotherapy, surgery needs to be undertaken along with immunotherapy for effective anti-cancer therapeutics.
“Global Peptide Cancer Vaccine Market & Clinical Pipeline Insight” Report Highlights:
With the ever increasing new cancer cases across the globe and the conventional treatment methods unable to cope up with the challenges posed by the tumor and their immune response evading techniques, cancer immunotherapy brings a ray of hope. Cancer immunotherapy allows the host’s immune cells to get sensitized with the tumor-associated antigens which in turn elicits B cell and T cell mediated immune response to target and eliminate tumor cells. This is the underlying principle of cancer immunotherapy.
Among different forms of cancer immunotherapy which includes monoclonal antibody based immunotherapy, antibody-drug conjugates, dendritic cell cancer vaccines and others, peptide cancer vaccine holds a special position due to its various inherent advantages associated with its mechanism of action, its manufacturing process and its user friendly compliance. This could be supported with the fact that the first cancer vaccine successfully launched in the market was provenge, a prostate cancer vaccine.
The market trends of peptide cancer vaccines are on a higher curve, thanks to so many favorable parameters associated with peptides. Peptide cancer vaccines are based on active immunotherapy which makes them more potent as the antibodies present in the body after the administration of the vaccine are already sensitized and are ready for their anti-tumor action. The response is permanent which lasts almost throughout the lifetime of the patient.Moreover, peptides are highly specific in their function which allows for the formulation of personalized cancer vaccine. As the tumor-associated antigens are protein sequence, they can be investigated and incorporated for the development of cancer vaccine based on that specific protein sequence to target only the tumor cells, avoiding the healthy cells hence reduced risk of toxicity.
With the development of next generation peptide cancer vaccines namely multivalent long peptides, peptide cocktail vaccines, hybrid peptide vaccines, personalized peptide vaccines and peptide-pulsed dendritic cell cancer vaccines among others, several challenges associated with the cancer immunotherapy will be addressed. The major hurdles for peptide cancer vaccines is the lack of standardized clinical trials success related parameters which has resulted in many clinical trials failures in the recent times. In addition to this, cancer cells are known to evade immune response by modulating the immune system, inducing immune-tolerance and initiating cancer-immunoediting.
What so ever be the challenges, the future of peptide cancer vaccine is extremely bright as it offers novel solutions to so many unanswered questions in cancer immunotherapy. As the knowledge of antigen, its action on the key components of the immune system is further understood, the efficacy of peptide vaccine will definitely increase. Until then, the best way forward for peptide cancer vaccine is to use multivalent long peptide sequence which is able to break immunotolerance and offer wide therapeutic action. Meanwhile investigators need to bring forward new clinical trials study parameters in line with the cancer vaccine program. For the patients at their advanced stage of cancer, the combinational therapy using conventional methods like chemotherapy, surgery needs to be undertaken along with immunotherapy for effective anti-cancer therapeutics.
“Global Peptide Cancer Vaccine Market & Clinical Pipeline Insight” Report Highlights:
- Introduction to Peptide cancer Vaccine
- Mechanism of Action of Peptide Cancer Vaccine
- Need of Peptide Cancer Vaccines
- Clinical Trials Efficacy Study of Synthetic Peptide Analog Obtained From WT1 Oncoprotein
- Wide Spectrum Action of Peptide Cancer Vaccines against Major Cancer
- Global Peptide Cancer Vaccine Pipeline: 41 Vaccines
- Global Peptide Cancer Vaccine Clinical Pipeline by Company, Indication & Phase
1. PEPTIDE CANCER VACCINE: INTRODUCTION
2. MECHANISM OF ACTION OF PEPTIDE CANCER VACCINES
2.1 Immunological Cells Activated by Peptide Cancer Vaccines
2.2 Procedure of Synthetic Peptide Vaccine Development
2.2.1 Determination of Antigen Components, Its Selection & Construction
2.2.2 Peptide Immunogen Construction
2.2.3 Immunogen Engineering Mechanism
2.2.4 Adjuvants Used for Peptide Cancer Vaccines
2.2.5 Investigation of Efficiency & Immune Response to Synthetic Peptide Cancer Vaccine
3. CLINICAL TRIALS EFFICACY STUDY OF SYNTHETIC PEPTIDE ANALOG OBTAINED FROM WT1 ONCOPROTEIN AGAINST ACUTE MYELOID LEUKEMIA
3.1 Basic Layout of the Study
3.2 Introduction to WT1 Peptide
3.3 Methodologies Involved In the Clinical Study
3.3.1 Trial Design Undertaken
3.3.2 Treatment Procedure
3.3.3 The Formulation of Vaccine Doses
3.3.4 Assessment of CD4+ T cell & CD8+ T Cell Responses
3.4 Results of the Clinical Trial Study
3.4.1 Patients Immunological Parameters & the Clinical Outcomes
3.4.2 Safety & Toxicity Related Clinical Outcomes
4. WIDE SPECTRUM ACTION OF PEPTIDE CANCER VACCINES AGAINST MAJOR CANCER
4.1 Peptides & Colorectal Cancer
4.2 Peptides & Lung Cancer
4.3 Peptides & Pancreatic Cancer
4.4 Peptides & Gastric Cancer
4.5 Peptides & Prostate Cancer
4.6 Peptides & Breast Cancer
5. RECENT TRENDS IN PEPTIDE CANCER VACCINE MARKET
5.1 Optimized Cryptic Peptides
5.2 Therapeutic CpG Peptide-Based Cancer Vaccine
5.3 Personalized Neoantigen Vaccination with Synthetic Long Peptides
5.4 Recombinant Peptide Vaccine
5.5 p53 Peptide-Pulsed Dendritic Cells Cancer Vaccines
6. GLOBAL PEPTIDE CANCER VACCINE PIPELINE OVERVIEW
7. THE MARKET DRIVING FACTORS: WHY PEPTIDE CANCER VACCINES?
7.1 An Active Immunotherapy
7.2 Personalized & Targeted Therapy
7.3 Highly Efficient, High Immunogenic Response Generating
7.4 Multiple Tumor Targeting Ability
7.5 A Viable Solution to Immunotolerance
7.6 Improves the Quality Of Life & is Cost Effective
8. THE CHALLENGES AHEAD FOR PEPTIDE CANCER VACCINE: WHY THE GOING COULD BE TOUGH?
8.1 The Parameters Related To the Clinical Trials
8.2 Single Antigen Based Peptide Vaccine: Highly Prone To Failure
8.3 Lack of Standardized Parameters for Assessing the Result of Clinical Trials
8.4 Variable Therapeutic Window for Different Patients
8.5 Cancer Immunoediting: The Three Es; Tumor Elimination, Equilibrium & Escape
9. GLOBAL PEPTIDE CANCER VACCINE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-III
10. CONCLUSION: PEPTIDE CANCER VACCINE; A PROMISING CANDIDATE OF CANCER IMMUNOTHERAPY
11. COMPETITIVE LANDSCAPE
11.1 Enzo Life Science (Alexis Biotech)
11.2 Antigen Express
11.3 BioLife Science
11.4 Immatics Biotechnologies
11.5 Immune Design
11.6 Imugene
11.7 Immunomedics
11.8 ISA Pharmaceuticals
11.9 Galena Biopharma
11.10 Generex Biotechnology Corporation
11.11 Lytix Biopharma
11.12 Merck (Merck Serono)
11.13 OncoTherapy Science
11.14 Oncothyreon
11.15 Pfizer
11.16 Phylogica
11.17 Symphogen (Receptor BioLogix)
11.18 Sumitomo Dainippon Pharma
11.19 TapImmune
11.20 Vaxon Biotech
2. MECHANISM OF ACTION OF PEPTIDE CANCER VACCINES
2.1 Immunological Cells Activated by Peptide Cancer Vaccines
2.2 Procedure of Synthetic Peptide Vaccine Development
2.2.1 Determination of Antigen Components, Its Selection & Construction
2.2.2 Peptide Immunogen Construction
2.2.3 Immunogen Engineering Mechanism
2.2.4 Adjuvants Used for Peptide Cancer Vaccines
2.2.5 Investigation of Efficiency & Immune Response to Synthetic Peptide Cancer Vaccine
3. CLINICAL TRIALS EFFICACY STUDY OF SYNTHETIC PEPTIDE ANALOG OBTAINED FROM WT1 ONCOPROTEIN AGAINST ACUTE MYELOID LEUKEMIA
3.1 Basic Layout of the Study
3.2 Introduction to WT1 Peptide
3.3 Methodologies Involved In the Clinical Study
3.3.1 Trial Design Undertaken
3.3.2 Treatment Procedure
3.3.3 The Formulation of Vaccine Doses
3.3.4 Assessment of CD4+ T cell & CD8+ T Cell Responses
3.4 Results of the Clinical Trial Study
3.4.1 Patients Immunological Parameters & the Clinical Outcomes
3.4.2 Safety & Toxicity Related Clinical Outcomes
4. WIDE SPECTRUM ACTION OF PEPTIDE CANCER VACCINES AGAINST MAJOR CANCER
4.1 Peptides & Colorectal Cancer
4.2 Peptides & Lung Cancer
4.3 Peptides & Pancreatic Cancer
4.4 Peptides & Gastric Cancer
4.5 Peptides & Prostate Cancer
4.6 Peptides & Breast Cancer
5. RECENT TRENDS IN PEPTIDE CANCER VACCINE MARKET
5.1 Optimized Cryptic Peptides
5.2 Therapeutic CpG Peptide-Based Cancer Vaccine
5.3 Personalized Neoantigen Vaccination with Synthetic Long Peptides
5.4 Recombinant Peptide Vaccine
5.5 p53 Peptide-Pulsed Dendritic Cells Cancer Vaccines
6. GLOBAL PEPTIDE CANCER VACCINE PIPELINE OVERVIEW
7. THE MARKET DRIVING FACTORS: WHY PEPTIDE CANCER VACCINES?
7.1 An Active Immunotherapy
7.2 Personalized & Targeted Therapy
7.3 Highly Efficient, High Immunogenic Response Generating
7.4 Multiple Tumor Targeting Ability
7.5 A Viable Solution to Immunotolerance
7.6 Improves the Quality Of Life & is Cost Effective
8. THE CHALLENGES AHEAD FOR PEPTIDE CANCER VACCINE: WHY THE GOING COULD BE TOUGH?
8.1 The Parameters Related To the Clinical Trials
8.2 Single Antigen Based Peptide Vaccine: Highly Prone To Failure
8.3 Lack of Standardized Parameters for Assessing the Result of Clinical Trials
8.4 Variable Therapeutic Window for Different Patients
8.5 Cancer Immunoediting: The Three Es; Tumor Elimination, Equilibrium & Escape
9. GLOBAL PEPTIDE CANCER VACCINE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-III
10. CONCLUSION: PEPTIDE CANCER VACCINE; A PROMISING CANDIDATE OF CANCER IMMUNOTHERAPY
11. COMPETITIVE LANDSCAPE
11.1 Enzo Life Science (Alexis Biotech)
11.2 Antigen Express
11.3 BioLife Science
11.4 Immatics Biotechnologies
11.5 Immune Design
11.6 Imugene
11.7 Immunomedics
11.8 ISA Pharmaceuticals
11.9 Galena Biopharma
11.10 Generex Biotechnology Corporation
11.11 Lytix Biopharma
11.12 Merck (Merck Serono)
11.13 OncoTherapy Science
11.14 Oncothyreon
11.15 Pfizer
11.16 Phylogica
11.17 Symphogen (Receptor BioLogix)
11.18 Sumitomo Dainippon Pharma
11.19 TapImmune
11.20 Vaxon Biotech
LIST OF FIGURES
Figure 1-1: Advantages of Peptide Cancer Vaccines
Figure 2-1: Immunological Cells Activated By Peptide Cancer Vaccines
Figure 2-2: Procedure of Synthetic Peptide Cancer Vaccine Development
Figure 2-3: Determination of Antigen Components, Its Selection & Construction
Figure 2-4: Role of Adjuvants in Peptide Cancer Vaccines
Figure 2-5: Investigation of Efficiency & Immune Response to Synthetic Peptide Cancer Vaccine
Figure 3-1: Clinical Trial Study of WT1 Peptide Vaccine for Acute Myeloid Leukemia Patients
Figure 3-2: WT1 Peptide as a Marker for Cancer Therapy
Figure 3-3: Methodologies Involved In the Clinical Study
Figure 4-1: Peptides & Colorectal Cancer
Figure 4-2: Peptides & Lung Cancer
Figure 4-3: Peptides & Pancreatic Cancer
Figure 4-4: Peptides & Gastric Cancer
Figure 4-5: Peptides & Prostate Cancer
Figure 4-6: Peptides & Breast Cancer
Figure 5-1: Optimized Cryptic Peptides
Figure 5-2: Therapeutic CpG Peptide-Based Cancer Vaccine
Figure 5-3: Personalized Neoantigen Vaccination with Synthetic Long Peptides
Figure 5-4: Recombinant Peptide Vaccine
Figure 5-5: p53 Peptide-Pulsed Dendritic Cells Cancer Vaccine
Figure 6-1: Peptide Cancer Vaccine Pipeline by Phase (%), 2016
Figure 6-2: Peptide Cancer Vaccine Pipeline by Phase (Numbers), 2016
Figure 7-1: Market Drivers of Peptide Cancer Vaccines
Figure 7-2: Peptide Cancer Vaccine: An Active Immunotherapy
Figure 7-3: Peptide Cancer Vaccine: A Personalized, Targeted Therapy
Figure 7-4: Peptide Cancer Vaccine: Highly Efficient, High Immunogenic Response Generating
Figure 7-5: Peptide Cancer Vaccine: Multiple Tumors Targeting Ability
Figure 7-6: Peptide Cancer Vaccine: A Viable Solution to Immunotolerance
Figure 7-7: Peptide Cancer Vaccine: Improves the Quality Of Life & is Cost Effective
Figure 8-1: Challenges of Peptide Cancer Vaccine: The Parameters Related To the Clinical Trials
Figure 8-2: Single Antigen Based Peptide Vaccine: Highly Prone To Failure
Figure 8-3: Lack of Standardized Parameters for Assessing the Result of Clinical Trials
Figure 8-4: Variable Therapeutic Window for Different Patients
Figure 8-5: Cancer Immunoediting: The Three Es; Tumor Elimination, Equilibrium & Escape
Figure 11-1: Enzo Life Science Pipeline
Figure 11-2: Immatics Biotechnologies Pipeline
Figure 11-3: Immune Design Pipeline
Figure 11-4: Imugene Pipeline
Figure 11-5: ISA Pharmaceuticals Pipeline
Figure 11-6: Galena Biopharma Pipeline
Figure 11-7: Generex Biotechnology Pipeline
Figure 11-8: Lytix Biopharma Pipeline
Figure 11-9: Merck Clinical Pipeline
Figure 11-10: Onco Therapy Science Pipeline
Figure 11-11: Oncothyreon Pipeline
Figure 11-12: Sumitomo Dainippon Pharma Pipeline
Figure 11-13: Tapimmune Pipeline
Figure 11-14: Vaxon Biotech Pipeline
Figure 1-1: Advantages of Peptide Cancer Vaccines
Figure 2-1: Immunological Cells Activated By Peptide Cancer Vaccines
Figure 2-2: Procedure of Synthetic Peptide Cancer Vaccine Development
Figure 2-3: Determination of Antigen Components, Its Selection & Construction
Figure 2-4: Role of Adjuvants in Peptide Cancer Vaccines
Figure 2-5: Investigation of Efficiency & Immune Response to Synthetic Peptide Cancer Vaccine
Figure 3-1: Clinical Trial Study of WT1 Peptide Vaccine for Acute Myeloid Leukemia Patients
Figure 3-2: WT1 Peptide as a Marker for Cancer Therapy
Figure 3-3: Methodologies Involved In the Clinical Study
Figure 4-1: Peptides & Colorectal Cancer
Figure 4-2: Peptides & Lung Cancer
Figure 4-3: Peptides & Pancreatic Cancer
Figure 4-4: Peptides & Gastric Cancer
Figure 4-5: Peptides & Prostate Cancer
Figure 4-6: Peptides & Breast Cancer
Figure 5-1: Optimized Cryptic Peptides
Figure 5-2: Therapeutic CpG Peptide-Based Cancer Vaccine
Figure 5-3: Personalized Neoantigen Vaccination with Synthetic Long Peptides
Figure 5-4: Recombinant Peptide Vaccine
Figure 5-5: p53 Peptide-Pulsed Dendritic Cells Cancer Vaccine
Figure 6-1: Peptide Cancer Vaccine Pipeline by Phase (%), 2016
Figure 6-2: Peptide Cancer Vaccine Pipeline by Phase (Numbers), 2016
Figure 7-1: Market Drivers of Peptide Cancer Vaccines
Figure 7-2: Peptide Cancer Vaccine: An Active Immunotherapy
Figure 7-3: Peptide Cancer Vaccine: A Personalized, Targeted Therapy
Figure 7-4: Peptide Cancer Vaccine: Highly Efficient, High Immunogenic Response Generating
Figure 7-5: Peptide Cancer Vaccine: Multiple Tumors Targeting Ability
Figure 7-6: Peptide Cancer Vaccine: A Viable Solution to Immunotolerance
Figure 7-7: Peptide Cancer Vaccine: Improves the Quality Of Life & is Cost Effective
Figure 8-1: Challenges of Peptide Cancer Vaccine: The Parameters Related To the Clinical Trials
Figure 8-2: Single Antigen Based Peptide Vaccine: Highly Prone To Failure
Figure 8-3: Lack of Standardized Parameters for Assessing the Result of Clinical Trials
Figure 8-4: Variable Therapeutic Window for Different Patients
Figure 8-5: Cancer Immunoediting: The Three Es; Tumor Elimination, Equilibrium & Escape
Figure 11-1: Enzo Life Science Pipeline
Figure 11-2: Immatics Biotechnologies Pipeline
Figure 11-3: Immune Design Pipeline
Figure 11-4: Imugene Pipeline
Figure 11-5: ISA Pharmaceuticals Pipeline
Figure 11-6: Galena Biopharma Pipeline
Figure 11-7: Generex Biotechnology Pipeline
Figure 11-8: Lytix Biopharma Pipeline
Figure 11-9: Merck Clinical Pipeline
Figure 11-10: Onco Therapy Science Pipeline
Figure 11-11: Oncothyreon Pipeline
Figure 11-12: Sumitomo Dainippon Pharma Pipeline
Figure 11-13: Tapimmune Pipeline
Figure 11-14: Vaxon Biotech Pipeline
